PL2069403T3 - Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4 - Google Patents

Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4

Info

Publication number: PL2069403T3
Authority: PL; Poland
Prior art keywords: human; receptor; high affinity; antibodies; human antibodies
Prior art date: 2006-10-02

Application number

PL07867197T

Other languages

English (en)

Inventor

Sean Stevens

Tammy T Huang

Joel H Martin

Jeanette L Fairhurst

Ashique Rafique

Marcela Torres

Kevin J Pobursky

Raymond W Leidich

Joan A Windsor

Warren R Mikulka

Diana M Ahrens

Ergang Shi

Nicholas J Papadopoulos

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-02

Filing date

2007-10-02

Publication date

2015-08-31

2007-10-02 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2015-08-31 Publication of PL2069403T3 publication Critical patent/PL2069403T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Zoology (AREA)
Physical Education & Sports Medicine (AREA)
Wood Science & Technology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Physics & Mathematics (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Plant Pathology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Hematology (AREA)

PL07867197T 2006-10-02 2007-10-02 Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4 PL2069403T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US84869406P	2006-10-02	2006-10-02
US95773807P	2007-08-24	2007-08-24
EP07867197.1A EP2069403B1 (en)	2006-10-02	2007-10-02	High affinity human antibodies to human il-4 receptor
PCT/US2007/021210 WO2008054606A2 (en)	2006-10-02	2007-10-02	High affinity human antibodies to human il-4 receptor

Publications (1)

Publication Number	Publication Date
PL2069403T3 true PL2069403T3 (pl)	2015-08-31

Family

ID=39344836

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL14162081T PL2769992T3 (pl)	2006-10-02	2007-10-02	Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4
PL07867197T PL2069403T3 (pl)	2006-10-02	2007-10-02	Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL14162081T PL2769992T3 (pl)	2006-10-02	2007-10-02	Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4

Country Status (35)

Country	Link
US (4)	US7605237B2 (pl)
EP (3)	EP2769992B1 (pl)
JP (1)	JP2010505418A (pl)
KR (1)	KR101474227B1 (pl)
CN (1)	CN101522716B (pl)
AU (1)	AU2007314522C9 (pl)
BR (1)	BRPI0719953B8 (pl)
CA (1)	CA2664343C (pl)
CO (1)	CO6160305A2 (pl)
CR (1)	CR10689A (pl)
CY (1)	CY1115551T1 (pl)
DK (2)	DK2069403T3 (pl)
DO (1)	DOP2009000058A (pl)
ES (2)	ES2466669T3 (pl)
HK (2)	HK1131790A1 (pl)
HR (2)	HRP20140512T1 (pl)
HU (1)	HUE054090T2 (pl)
IL (1)	IL197479A (pl)
LT (1)	LT2769992T (pl)
MA (1)	MA31138B1 (pl)
ME (1)	MEP11109A (pl)
MX (1)	MX2009003393A (pl)
MY (1)	MY149079A (pl)
NI (1)	NI200900041A (pl)
NO (1)	NO347180B1 (pl)
NZ (1)	NZ576040A (pl)
PL (2)	PL2769992T3 (pl)
PT (2)	PT2769992T (pl)
RS (2)	RS53340B (pl)
RU (1)	RU2445318C2 (pl)
SI (2)	SI2069403T1 (pl)
TN (1)	TN2009000110A1 (pl)
UA (1)	UA98943C2 (pl)
WO (1)	WO2008054606A2 (pl)
ZA (1)	ZA200901617B (pl)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050144655A1 (en)	2000-10-31	2005-06-30	Economides Aris N.	Methods of modifying eukaryotic cells
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
DK2314629T4 (da)	2002-07-18	2023-02-06	Merus Nv	Rekombinant produktion af blandinger af antistoffer
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
ES2408582T3 (es)	2003-05-30	2013-06-21	Merus B.V.	Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US7608693B2 (en) *	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
ES2518415T3 (es)	2007-12-21	2014-11-05	Medimmune Limited	Elementos de unión para receptor alfa de interleucina-4 (IL-4Ralfa)
PT2147594E (pt)	2008-06-27	2014-02-17	Merus B V	Mamíferos não humanos que produzem anticorpos
US8871207B2 (en)	2008-07-25	2014-10-28	Humabs, LLC	Neutralizing anti-influenza A virus antibodies and uses thereof
BRPI0911699B8 (pt) *	2008-07-25	2023-02-28	Inst Res Biomedicine	vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
AU2014216019B2 (en) *	2008-10-29	2016-04-21	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to Human IL-4 receptor
US20130064834A1 (en)	2008-12-15	2013-03-14	Regeneron Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2564695B1 (en)	2009-07-08	2015-04-15	Kymab Limited	Animal models and therapeutic molecules
US20120204278A1 (en)	2009-07-08	2012-08-09	Kymab Limited	Animal models and therapeutic molecules
US9445581B2 (en)	2012-03-28	2016-09-20	Kymab Limited	Animal models and therapeutic molecules
US20130045492A1 (en)	2010-02-08	2013-02-21	Regeneron Pharmaceuticals, Inc.	Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en)	2010-02-08	2017-10-24	Regeneron Pharmaceuticals, Inc.	Mice expressing a limited immunoglobulin light chain repertoire
EP2501817B2 (en)	2010-02-08	2021-04-21	Regeneron Pharmaceuticals, Inc.	Common light chain mouse
CN103068993B (zh)	2010-06-22	2016-01-06	瑞泽恩制药公司	杂交轻链小鼠
ES2612459T3 (es)	2010-08-02	2017-05-17	Regeneron Pharmaceuticals, Inc.	Ratones que producen proteínas de unión que comprenden dominios VL
JP5918246B2 (ja)	2010-10-06	2016-05-18	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
AU2012258637B2 (en)	2011-05-24	2017-07-20	Zyngenia, Inc.	Multivalent and monovalent multispecific complexes and their uses
CN102830228B (zh) *	2011-06-15	2015-01-21	格诺思博生物科技(上海)有限公司	定量分析循环肿瘤细胞的试剂及试剂盒
JO3412B1 (ar) *	2011-06-17	2019-10-20	Regeneron Pharma	أجسام مضادة ل angptl3 واستخداماتها
LT2731677T (lt) *	2011-07-11	2018-07-10	Glenmark Pharmaceuticals S.A.	Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas
US9587010B2 (en)	2011-07-18	2017-03-07	The Institute For Research In Biomedicine	Neutralizing anti-influenza A virus antibodies and uses thereof
NZ781020A (en)	2011-08-05	2023-01-27	Regeneron Pharma	Humanized universal light chain mice
CN111789944A (zh)	2011-09-16	2020-10-20	瑞泽恩制药公司	用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
CN106995822B (zh) *	2011-09-19	2021-06-29	科马布有限公司	定制供人类使用的抗体、可变结构域和链
CA2791109C (en)	2011-09-26	2021-02-16	Merus B.V.	Generation of binding molecules
EP2761008A1 (en)	2011-09-26	2014-08-06	Kymab Limited	Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en)	2012-03-28	2016-02-09	Kymab Limited	Animal models and therapeutic molecules
KR102186822B1 (ko)	2011-12-20	2020-12-04	리제너론 파마슈티칼스 인코포레이티드	인간화 경쇄 마우스
KR102228296B1 (ko)	2012-03-16	2021-03-17	리제너론 파마슈티칼스 인코포레이티드	히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
WO2013138712A1 (en)	2012-03-16	2013-09-19	Regeneron Pharmaceuticals, Inc.	Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en)	2012-03-16	2014-01-09	Regeneron Pharmaceuticals, Inc.	Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP2825035A1 (en)	2012-03-16	2015-01-21	Regeneron Pharmaceuticals, Inc.	Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en)	2012-05-17	2013-11-20	Kymab Ltd	Multivalent antibodies and in vivo methods for their production
US10251377B2 (en)	2012-03-28	2019-04-09	Kymab Limited	Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
PT2838918T (pt)	2012-04-20	2019-08-23	Merus Nv	Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
JP6306588B2 (ja)	2012-08-21	2018-04-04	サノフィ・バイオテクノロジー	Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
TWI682941B (zh)	2013-02-01	2020-01-21	美商再生元醫藥公司	含嵌合恆定區之抗體
BR112015019350A2 (pt) *	2013-02-20	2017-08-22	Regeneron Pharma	Animal não humano, locus de imunoglobulina, e, métodos de fabricação de um animal não humano, para a obtenção de uma sequência de ácido nucleico e de fabricação de uma proteína de ligação ao antígeno
EP3896088A1 (en) *	2013-02-20	2021-10-20	Innate Pharma	Treatment of peripheral t cell lymphoma
CN105451767B (zh)	2013-03-15	2019-10-18	泽恩格尼亚股份有限公司	多价和单价多特异性复合物及其用途
US9788534B2 (en)	2013-03-18	2017-10-17	Kymab Limited	Animal models and therapeutic molecules
US9783618B2 (en)	2013-05-01	2017-10-10	Kymab Limited	Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en)	2013-05-02	2017-10-10	Kymab Limited	Antibodies, variable domains and chains tailored for human use
US11707056B2 (en)	2013-05-02	2023-07-25	Kymab Limited	Animals, repertoires and methods
US10111953B2 (en)	2013-05-30	2018-10-30	Regeneron Pharmaceuticals, Inc.	Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI633891B (zh)	2013-06-04	2018-09-01	再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
RU2674680C2 (ru)	2013-06-21	2018-12-12	Санофи Байотекнолоджи	Способы лечения полипоза носа путем введения антагониста il-4r
TWI634900B (zh)	2013-07-11	2018-09-11	再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
NL2013554B1 (en)	2013-10-01	2016-01-08	Kymab Ltd	Animal models and therapeutic molecules.
CN105848722B (zh)	2013-10-02	2021-09-03	免疫医疗有限责任公司	中和抗甲型流感抗体及其用途
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE202014010499U1 (de)	2013-12-17	2015-10-20	Kymab Limited	Targeting von humaner PCSK9 zur Cholesterinbehandlung
SG10201806481XA (en) *	2014-02-19	2018-09-27	Emergent Biosolutions Canada Inc	Marburg monoclonal antibodies
CA2940295A1 (en)	2014-02-21	2015-08-27	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4r antagonist
CA2939506C (en)	2014-02-28	2022-08-23	Regeneron Pharmaceuticals, Inc.	Methods for treating skin infection by administering an il-4r antagonist
SG11201607015VA (en)	2014-03-21	2016-09-29	Regeneron Pharma	V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
SG11201607203XA (en)	2014-03-21	2016-09-29	Regeneron Pharma	Non-human animals that make single domain binding proteins
WO2016011035A2 (en)	2014-07-15	2016-01-21	Medlmmune, Llc	Neutralizing anti-influenza b antibodies and uses thereof
WO2016023916A1 (en)	2014-08-12	2016-02-18	Kymab Limited	Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en)	2014-11-07	2016-05-12	Kymab Limited	Treatment of disease using ligand binding to targets of interest
MX2017006286A (es)	2014-11-14	2018-01-23	Sanofi Biotechnology	Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
AU2016229996A1 (en) *	2015-03-06	2017-09-28	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind JAG1
AU2016232715A1 (en)	2015-03-19	2017-09-28	Regeneron Pharmaceuticals, Inc.	Non-human animals that select for light chain variable regions that bind antigen
CA2981312C (en)	2015-03-30	2023-09-26	Regeneron Pharmaceuticals, Inc.	Heavy chain constant regions with reduced binding to fc gamma receptors
CN107683291B (zh) *	2015-04-02	2021-11-19	英特维特国际股份有限公司	针对犬白介素-4受体α的抗体
CN113480640A (zh)	2015-06-01	2021-10-08	免疫医疗有限责任公司	中和抗流感结合分子及其用途
CN106699888B (zh) *	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	一种pd-1抗体及其制备方法和应用
CN106939047B (zh) *	2016-01-04	2021-08-31	江苏怀瑜药业有限公司	一种pd-l1抗体及其制备方法
WO2017123685A1 (en)	2016-01-13	2017-07-20	Medimmune, Llc	Method of treating influenza a
US10314904B2 (en)	2016-02-19	2019-06-11	Regeneron Pharmaceuticals, Inc.	Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
CN107474134B (zh) *	2016-06-08	2021-07-27	苏州康乃德生物医药有限公司	用于结合白细胞介素4受体的抗体
CA3035202A1 (en)	2016-09-01	2018-03-08	Regeneron Pharmaceuticals, Inc.	Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en)	2016-09-22	2018-03-29	Regeneron Pharmaceuticals, Inc.	Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
IL265516B1 (en)	2016-09-22	2024-02-01	Regeneron Pharma	Methods for treating severe allergic dermatitis by administering an il-4r inhibitor
EP3525820A4 (en) *	2016-10-17	2020-09-16	Vanderbilt University	ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS AND THEIR USE METHODS
TWI784988B (zh)	2016-12-01	2022-12-01	美商再生元醫藥公司	治療發炎症狀的方法
US11702481B2 (en)	2016-12-16	2023-07-18	Bluefin Biomedicine, Inc.	Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
JP7321939B2 (ja)	2017-04-13	2023-08-07	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
CN107216388B (zh) *	2017-08-07	2020-05-05	广州泰诺迪生物科技有限公司	一种治疗丙型肝炎病毒药物的制备方法和用途
CA3079946A1 (en)	2017-10-30	2019-05-09	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4r antagonist
CN108373505B (zh)	2018-04-20	2019-08-20	北京智仁美博生物科技有限公司	抗il-4r抗体及其用途
MA52624A (fr)	2018-05-13	2021-03-24	Regeneron Pharma	Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
CN113101364B (zh) *	2018-05-29	2023-12-01	康诺亚生物医药科技（成都）有限公司	一种自免疫抑制剂的开发和应用
AU2019308205A1 (en) *	2018-07-16	2020-11-19	Regeneron Pharmaceuticals, Inc.	Non-human animal models of DITRA disease and uses thereof
EP3808774A4 (en)	2018-08-24	2021-08-18	Jiangsu Hengrui Medicine Co., Ltd.	HUMAN IL-4R BINDING ANTIBODIES, ANTIGEN BINDING FRAGMENT AND RELATED MEDICAL USE
EP3878868A4 (en) *	2018-11-09	2022-07-27	Ajou University Industry-Academic Cooperation Foundation	HUMAN ANTIBODY WITH HIGH AFFINITY TO AND USE OF HUMAN IL-4 RECEPTOR ALPHA
CN110746507B (zh)	2018-12-25	2020-06-26	江苏荃信生物医药有限公司	抗人白介素4受体α单克隆抗体及其应用
WO2020180727A1 (en)	2019-03-06	2020-09-10	Regeneron Pharmaceuticals, Inc.	Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
AU2020240132A1 (en)	2019-03-21	2021-09-16	Regeneron Pharmaceuticals, Inc.	Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
KR20210150432A (ko) *	2019-04-08	2021-12-10	페인스 테라퓨틱스 인코포레이티드	인간화 항-dll3 키메라 항원 수용체 및 이의 용도
CN112010977B (zh) *	2019-05-29	2022-04-26	山东博安生物技术股份有限公司	抗白介素4受体(il-4r)的抗体及其应用
CN112279914A (zh) *	2019-07-25	2021-01-29	苏州丁孚靶点生物技术有限公司	Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂
US20210040222A1 (en)	2019-08-05	2021-02-11	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en)	2019-08-05	2022-11-22	Regeneron Pharmaceuticals, Inc.	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
KR20220110829A (ko)	2019-12-09	2022-08-09	사노피 바이오테크놀로지	디지털 식별된 il-4/il-13 관련 장애의 치료 방법
EP3992974A1 (en)	2020-11-02	2022-05-04	Sanofi Biotechnology	Methods for treating digitally-identified il-4/il-13 related disorders
US20230075244A1 (en) *	2020-02-20	2023-03-09	The Feinstein Institutes For Medical Research	Agonist antibodies against endoglin and uses thereof
MX2022010217A (es)	2020-02-21	2022-09-19	Jiangsu Hengrui Pharmaceuticals Co Ltd	Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.
BR112022017174A2 (pt) *	2020-02-27	2022-10-18	Chia Tai Tianqing Pharmaceutical Group Co Ltd	Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
MX2022011730A (es)	2020-03-27	2022-10-13	Regeneron Pharma	Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
CA3179805A1 (en) *	2020-04-10	2021-10-14	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein
CN113527485A (zh)	2020-04-17	2021-10-22	上海麦济生物技术有限公司	抗人白细胞介素-4受体α抗体及其制备方法和应用
CN113549151A (zh) *	2020-04-24	2021-10-26	苏州康乃德生物医药有限公司	与人IL-4Rα中特定表位结合的抗体及其应用
EP4153300A1 (en)	2020-05-22	2023-03-29	Regeneron Pharmaceuticals, Inc.	Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
US20230279124A1 (en) *	2020-07-17	2023-09-07	Gi Innovation, Inc.	Fusion protein comprising ige fc receptor alpha subunit extracellular domain and anti-il-4r antibody, and use thereof
KR20220035655A (ko)	2020-09-14	2022-03-22	아주대학교산학협력단	인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
BR112023004020A2 (pt)	2020-10-05	2023-04-25	Sanofi Biotechnology	Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
MX2023007178A (es)	2020-12-22	2023-06-30	Jiangsu Hengrui Pharmaceuticals Co Ltd	Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo.
CA3204552A1 (en) *	2021-01-08	2022-07-14	Joseph M. LUETTGEN	Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
US20220220211A1 (en)	2021-01-08	2022-07-14	Regeneron Pharmaceuticals, Inc.	Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
AU2022316939A1 (en)	2021-07-26	2024-03-07	Regeneron Pharmaceuticals, Inc.	Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
TW202328183A (zh) *	2021-08-05	2023-07-16	美商美國禮來大藥廠	人類介白素-4受體α抗體
IL310962A (en)	2021-08-23	2024-04-01	Regeneron Pharma	Methods for treating atopic dermatitis by administering an IL-4R antagonist
AU2022369296A1 (en)	2021-10-20	2024-05-30	Regeneron Pharmaceuticals, Inc.	Methods for treating prurigo nodularis by administering an il-4r antagonist
WO2023130010A1 (en)	2021-12-30	2023-07-06	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
US20240010737A1 (en)	2022-03-02	2024-01-11	Regeneron Pharmaceuticals, Inc.	Manufacturing process for high titer antibody
WO2023215267A1 (en)	2022-05-02	2023-11-09	Regeneron Pharmaceuticals, Inc.	Anti-interleukin-4 receptor (il-4r) antibody formulations
WO2023215750A2 (en)	2022-05-02	2023-11-09	Regeneron Pharmaceuticals, Inc.	Methods for reducing lipase activity
US20240034798A1 (en)	2022-07-08	2024-02-01	Regeneron Pharmaceuticals, Inc.	Methods for treating eosinophilic esophagitis by administering an il-4r antagonist
WO2024047021A1 (en)	2022-08-29	2024-03-07	Sanofi	Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
WO2024097714A1 (en)	2022-11-01	2024-05-10	Regeneron Pharmaceuticals, Inc.	Methods for treating hand and foot dermatitis by administering an il-4r antagonist

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US809A (en)		1838-06-27		Improved mode of changing the poles of electro-magnets
US7186A (en)		1850-03-19		fetchec
GB8808015D0 (en)	1988-04-06	1988-05-05	Ritter M A	Chemical compounds
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
WO1990005183A1 (en) *	1988-10-31	1990-05-17	Immunex Corporation	Interleukin-4 receptors
AU675661B2 (en)	1992-07-24	1997-02-13	Abgenix, Inc.	Generation of xenogeneic antibodies
US5714146A (en)	1992-08-26	1998-02-03	Board Of Regents Of The University Of Washington	IL-4 bone therapy
EP0604693A1 (en) *	1992-12-29	1994-07-06	Schering-Plough	Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) *	1993-09-07	2001-02-10	Смитклайн Бичам Корпорейшн	Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2990420B1 (en) *	2000-05-26	2016-12-21	Immunex Corporation	Use of interleukin-4 receptor antibodies and compositions thereof
US7879328B2 (en) *	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
EP2298717B1 (en) *	2001-11-30	2015-10-28	Biogen MA Inc.	Antibodies against monocyte chemotactic proteins
US20040101920A1 (en)	2002-11-01	2004-05-27	Czeslaw Radziejewski	Modification assisted profiling (MAP) methodology
UA93653C2 (ru) *	2003-11-07	2011-03-10	Иммунекс Корпорейшн	Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7884054B2 (en) *	2003-12-22	2011-02-08	Amgen Inc.	Methods for identifying functional antibodies
ATE395358T1 (de) *	2004-02-27	2008-05-15	Regeneron Pharma	Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
US20090098142A1 (en) *	2004-06-09	2009-04-16	Kasaian Marion T	Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) *	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
TW200902555A (en)	2005-01-03	2009-01-16	Hoffmann La Roche	Antibodies against IL-13 receptor alpha 1 and uses thereof
US7608693B2 (en) *	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor

2007
- 2007-10-02 HU HUE14162081A patent/HUE054090T2/hu unknown
- 2007-10-02 RS RS20140308A patent/RS53340B/en unknown
- 2007-10-02 DK DK07867197.1T patent/DK2069403T3/da active
- 2007-10-02 ES ES07867197.1T patent/ES2466669T3/es active Active
- 2007-10-02 JP JP2009531433A patent/JP2010505418A/ja active Pending
- 2007-10-02 MY MYPI20091180A patent/MY149079A/en unknown
- 2007-10-02 AU AU2007314522A patent/AU2007314522C9/en active Active
- 2007-10-02 US US11/906,517 patent/US7605237B2/en active Active
- 2007-10-02 CN CN200780036872.1A patent/CN101522716B/zh active Active
- 2007-10-02 WO PCT/US2007/021210 patent/WO2008054606A2/en active Application Filing
- 2007-10-02 KR KR1020097008844A patent/KR101474227B1/ko active IP Right Grant
- 2007-10-02 PT PT141620815T patent/PT2769992T/pt unknown
- 2007-10-02 NZ NZ576040A patent/NZ576040A/en unknown
- 2007-10-02 MX MX2009003393A patent/MX2009003393A/es active IP Right Grant
- 2007-10-02 PL PL14162081T patent/PL2769992T3/pl unknown
- 2007-10-02 PT PT78671971T patent/PT2069403E/pt unknown
- 2007-10-02 UA UAA200904256A patent/UA98943C2/ru unknown
- 2007-10-02 RS RS20210392A patent/RS61650B1/sr unknown
- 2007-10-02 BR BRPI0719953A patent/BRPI0719953B8/pt active IP Right Grant
- 2007-10-02 SI SI200731493T patent/SI2069403T1/sl unknown
- 2007-10-02 DK DK14162081.5T patent/DK2769992T3/da active
- 2007-10-02 NO NO20091758A patent/NO347180B1/no unknown
- 2007-10-02 EP EP14162081.5A patent/EP2769992B1/en active Active
- 2007-10-02 EP EP20207210.4A patent/EP3845563A3/en active Pending
- 2007-10-02 SI SI200732172T patent/SI2769992T1/sl unknown
- 2007-10-02 EP EP07867197.1A patent/EP2069403B1/en active Active
- 2007-10-02 RU RU2009116608/10A patent/RU2445318C2/ru active
- 2007-10-02 LT LTEP14162081.5T patent/LT2769992T/lt unknown
- 2007-10-02 CA CA2664343A patent/CA2664343C/en active Active
- 2007-10-02 PL PL07867197T patent/PL2069403T3/pl unknown
- 2007-10-02 ME MEP-111/09A patent/MEP11109A/xx unknown
- 2007-10-02 ES ES14162081T patent/ES2859825T3/es active Active
2009
- 2009-03-06 ZA ZA2009/01617A patent/ZA200901617B/en unknown
- 2009-03-08 IL IL197479A patent/IL197479A/en active IP Right Grant
- 2009-03-24 CR CR10689A patent/CR10689A/es unknown
- 2009-03-30 NI NI200900041A patent/NI200900041A/es unknown
- 2009-03-31 TN TN2009000110A patent/TN2009000110A1/fr unknown
- 2009-04-01 DO DO2009000058A patent/DOP2009000058A/es unknown
- 2009-04-30 CO CO09044043A patent/CO6160305A2/es unknown
- 2009-04-30 MA MA31835A patent/MA31138B1/fr unknown
- 2009-09-04 US US12/554,029 patent/US7794717B2/en active Active
- 2009-10-21 HK HK09109758.4A patent/HK1131790A1/xx unknown
2010
- 2010-06-23 US US12/821,499 patent/US8092802B2/en active Active
2011
- 2011-12-02 US US13/309,594 patent/US8338135B2/en active Active
2014
- 2014-06-03 HR HRP20140512TT patent/HRP20140512T1/hr unknown
- 2014-08-07 CY CY20141100620T patent/CY1115551T1/el unknown
2015
- 2015-02-04 HK HK15101192.7A patent/HK1200846A1/xx unknown
2021
- 2021-03-10 HR HRP20210408TT patent/HRP20210408T1/hr unknown

Also Published As

Publication number	Publication date
KR101474227B1 (ko)	2014-12-18
EP2069403A2 (en)	2009-06-17
RU2445318C2 (ru)	2012-03-20
US7605237B2 (en)	2009-10-20
RS53340B (en)	2014-10-31
PL2769992T3 (pl)	2021-08-02
BRPI0719953B1 (pt)	2019-04-24
AU2007314522C1 (en)	2013-06-27
UA98943C2 (ru)	2012-07-10
ZA200901617B (en)	2009-12-30
KR20090088865A (ko)	2009-08-20
NO20091758L (no)	2009-05-04
AU2007314522A2 (en)	2009-07-02
EP2069403B1 (en)	2014-05-07
EP2769992A3 (en)	2015-01-21
CA2664343A1 (en)	2008-05-08
CA2664343C (en)	2016-04-26
TN2009000110A1 (en)	2010-08-19
SI2769992T1 (sl)	2021-04-30
RU2009116608A (ru)	2010-11-10
HK1200846A1 (en)	2015-08-14
US20100291107A1 (en)	2010-11-18
EP3845563A3 (en)	2021-11-24
US8338135B2 (en)	2012-12-25
PT2769992T (pt)	2021-03-11
BRPI0719953A2 (pt)	2014-04-29
HRP20210408T1 (hr)	2021-04-30
WO2008054606A2 (en)	2008-05-08
SI2069403T1 (sl)	2014-09-30
HUE054090T2 (hu)	2021-08-30
ME00616B (me)	2011-12-20
IL197479A (en)	2014-03-31
IL197479A0 (en)	2011-08-01
RS61650B1 (sr)	2021-04-29
WO2008054606A3 (en)	2009-02-05
ES2466669T3 (es)	2014-06-10
ES2859825T3 (es)	2021-10-04
AU2007314522B2 (en)	2013-02-21
JP2010505418A (ja)	2010-02-25
DK2069403T3 (da)	2014-07-28
LT2769992T (lt)	2021-04-12
CR10689A (es)	2009-06-24
AU2007314522B8 (en)	2013-04-11
MX2009003393A (es)	2009-05-11
CN101522716B (zh)	2013-03-20
US20120135010A1 (en)	2012-05-31
MY149079A (en)	2013-07-15
US7794717B2 (en)	2010-09-14
NI200900041A (es)	2011-10-17
AU2007314522C9 (en)	2013-08-01
DK2769992T3 (da)	2021-03-22
US20100021476A1 (en)	2010-01-28
EP2769992B1 (en)	2020-12-30
HRP20140512T1 (hr)	2014-07-04
CY1115551T1 (el)	2017-01-04
NO347180B1 (no)	2023-06-19
EP2769992A2 (en)	2014-08-27
MEP11109A (en)	2011-12-20
HK1131790A1 (en)	2010-02-05
DOP2009000058A (es)	2009-04-30
AU2007314522A1 (en)	2008-05-08
NZ576040A (en)	2011-06-30
CO6160305A2 (es)	2010-05-20
PT2069403E (pt)	2014-07-18
AU2007314522A8 (en)	2013-04-11
MA31138B1 (fr)	2010-02-01
EP3845563A2 (en)	2021-07-07
US20080160035A1 (en)	2008-07-03
CN101522716A (zh)	2009-09-02
BRPI0719953B8 (pt)	2021-05-25
US8092802B2 (en)	2012-01-10

Publication	Publication Date	Title
HK1200846A1 (en)	2015-08-14	High affinity human antibodies to human il-4 receptor il-4
HRP20130467T1 (en)	2013-06-30	High affinity human antibodies to human il-4 receptor
HUS1700029I1 (hu)	2017-07-28	Nagy affinitású PCSK9 elleni humán testek
EP2220247A4 (en)	2011-10-26	ANTIBODIES DIRECTED AGAINST LRP6
IL196701A0 (en)	2011-08-01	HUMAN ANTIBODIES TO ErbB2
IL197937A0 (en)	2011-08-01	Antibodies to lymphotoxin-alpha
ZA200902346B (en)	2010-07-28	Antibodies to lymphotoxin-alpha
ZA200809771B (en)	2009-11-25	High affinity antibodies to human IL-6 receptor